Drug
GV20-0251
GV20-0251 is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
4(80%)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting4
Not yet recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
4
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
recruiting480%
not_yet_recruiting120%
Recent Activity
4 active trials
Showing 5 of 5
recruitingphase_1
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
NCT07457281
not_yet_recruitingphase_1
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
NCT07307053
recruitingphase_1
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07070518
recruitingphase_1
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT07106827
recruitingphase_1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
NCT05669430
Clinical Trials (5)
Showing 5 of 5 trials
NCT07457281Phase 1
GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study
NCT07307053Phase 1
Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)
NCT07070518Phase 1
Study of GV20-0251 in Participants With Solid Tumor Malignancies
NCT07106827Phase 1
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
NCT05669430Phase 1
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5